Sulfatide Analysis by Mass Spectrometry for Screening of Metachromatic Leukodystrophy in Dried Blood and Urine Samples
Open Access
- 1 January 2016
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 62 (1), 279-286
- https://doi.org/10.1373/clinchem.2015.245159
Abstract
BACKGROUND: Metachromatic leukodystrophy (MLD) is an autosomal recessive disorder caused by deficiency in arylsulfatase A activity, leading to accumulation of sulfatide substrates. Diagnostic and monitoring procedures include demonstration of reduced arylsulfatase A activity in peripheral blood leukocytes or detection of sulfatides in urine. However, the development of a screening test is challenging because of instability of the enzyme in dried blood spots (DBS), the widespread occurrence of pseudodeficiency alleles, and the lack of available urine samples from newborn screening programs.METHODS: We measured individual sulfatide profiles in DBS and dried urine spots (DUS) from MLD patients with LC-MS/MS to identify markers with the discriminatory power to differentiate affected individuals from controls. We also developed a method for converting all sulfatide molecular species into a single species, allowing quantification in positive-ion mode upon derivatization.RESULTS: In DBS from MLD patients, we found up to 23.2-fold and 5.1-fold differences in total sulfatide concentrations for early- and late-onset MLD, respectively, compared with controls and pseudodeficiencies. Corresponding DUS revealed up to 164-fold and 78-fold differences for early- and late-onset MLD patient samples compared with controls. The use of sulfatides converted to a single species simplified the analysis and increased detection sensitivity in positive-ion mode, providing a second option for sulfatide analysis.CONCLUSIONS: This study of sulfatides in DBS and DUS suggests the feasibility of the mass spectrometry method for newborn screening of MLD and sets the stage for a larger-scale newborn screening pilot study.Keywords
Funding Information
- BioMarin Pharmaceutical
- Genzyme
- PerkinElmer
- Shire
- National Institute of Diabetes and Digestive and Kidney Diseases
- NIH (R01 DK067859)
This publication has 19 references indexed in Scilit:
- Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease PatientsPLOS ONE, 2013
- Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic LeukodystrophyScience, 2013
- High-Throughput Assay of 9 Lysosomal Enzymes for Newborn ScreeningClinical Chemistry, 2013
- Gb3/creatinine biomarkers for Fabry disease: Issues to considerMolecular Genetics and Metabolism, 2009
- Falsely elevated urinary Gb3 (globotriaosylceramide, CTH, GL3)Molecular Genetics and Metabolism, 2009
- Diagnosis of Metachromatic Leukodystrophy by Immune Quantification of Arylsulphatase A Protein and Activity in Dried Blood SpotsClinical Chemistry, 2008
- Characterization of Urinary Sulfatides in Metachromatic Leukodystrophy Using Electrospray Ionization-Tandem Mass SpectrometryMolecular Genetics and Metabolism, 2001
- Determination of Urinary Sulfatides and Other Lipids by Combination of Reversed-Phase and Thin-Layer ChromatographiesAnalytical Biochemistry, 1999
- Analysis of fatty acids and sphingosines from urinary sulfatides in a patient with metachromatic leukodystrophy by gas chromatography — Mass spectrometryBrain & Development, 1985
- Pseudo arylsulfatase a deficiency: Evidence for a structurally altered enzymeBiochemical and Biophysical Research Communications, 1983